Ignite Creation Date:
2025-12-24 @ 7:32 PM
Ignite Modification Date:
2025-12-25 @ 5:14 PM
Study NCT ID:
NCT00042003
Status:
COMPLETED
Last Update Posted:
2024-08-02
First Post:
2002-07-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Sponsor:
Astex Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2002-07
Start Date Type:
None
Primary Completion Date:
2004-12
Primary Completion Date Type:
ACTUAL
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2002-07-19
First Submit QC Date:
None
Study First Post Date:
2002-07-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-01
Last Update Post Date:
2024-08-02
Last Update Post Date Type:
ACTUAL